Literature DB >> 29700117

Sterol carrier protein-2 deficiency attenuates diet-induced dyslipidemia and atherosclerosis in mice.

Hongliang He1, Jing Wang1, Paul J Yannie2, Genta Kakiyama2, William J Korzun3, Shobha Ghosh4,2.   

Abstract

Intracellular cholesterol transport proteins move cholesterol to different subcellular compartments and thereby regulate its final metabolic fate. In hepatocytes, for example, delivery of high-density lipoprotein (HDL)-associated cholesterol for bile acid synthesis or secretion into bile facilitates cholesterol elimination from the body (anti-atherogenic effect), whereas delivery for esterification and subsequent incorporation into apolipoprotein B-containing atherogenic lipoproteins (e.g. very-low-density lipoprotein (VLDL)) enhances cholesterol secretion into the systemic circulation (pro-atherogenic effect). Intracellular cholesterol transport proteins such as sterol carrier protein-2 (SCP2) should, therefore, play a role in regulating these pro- or anti-atherosclerotic processes. Here, we sought to evaluate the effects of SCP2 deficiency on the development of diet-induced atherosclerosis. We generated LDLR-/- mice deficient in SCP2/SCPx (LS) and examined the effects of this deficiency on Western diet-induced atherosclerosis. SCP2/SCPx deficiency attenuated atherosclerosis in LS mice by >80% and significantly reduced plasma cholesterol and triglyceride levels. Investigation of the likely underlying mechanisms revealed a significant reduction in intestinal cholesterol absorption (given as an oral gavage) in SCP2/SCPx-deficient mice. Consistently, siRNA-mediated knockdown of SCP2 in intestinal cells significantly reduced cholesterol uptake. Furthermore, hepatic triglyceride/VLDL secretion from the liver or hepatocytes isolated from SCP2/SCPx-deficient mice was significantly reduced. These results indicate an important regulatory role for SCP2 deficiency in attenuating diet-induced atherosclerosis by limiting intestinal cholesterol absorption and decreasing hepatic triglyceride/VLDL secretion. These findings suggest targeted inhibition of SCP2 as a potential therapeutic strategy to reduce Western diet-induced dyslipidemia and atherosclerosis.

Entities:  

Keywords:  anti-atherogenic effect; atherosclerosis; cardiovascular disease; cholesterol metabolism; cholesterol-binding protein; diet; dyslipidemia; hepatic VLDL secretion; intracellular cholesterol transport; sterol carrier protein

Mesh:

Substances:

Year:  2018        PMID: 29700117      PMCID: PMC6005425          DOI: 10.1074/jbc.RA118.002290

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

Review 1.  StAR-related lipid transfer (START) proteins: mediators of intracellular lipid metabolism.

Authors:  Raymond E Soccio; Jan L Breslow
Journal:  J Biol Chem       Date:  2003-04-30       Impact factor: 5.157

Review 2.  Sterol carrier protein-2.

Authors:  U Seedorf; P Ellinghaus; J Roch Nofer
Journal:  Biochim Biophys Acta       Date:  2000-06-26

3.  Intracellular cholesterol-binding proteins enhance HDL-mediated cholesterol uptake in cultured primary mouse hepatocytes.

Authors:  Stephen M Storey; Avery L McIntosh; Huan Huang; Kerstin K Landrock; Gregory G Martin; Danilo Landrock; H Ross Payne; Barbara P Atshaves; Ann B Kier; Friedhelm Schroeder
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-01-12       Impact factor: 4.052

Review 4.  Gene structure, intracellular localization, and functional roles of sterol carrier protein-2.

Authors:  A M Gallegos; B P Atshaves; S M Storey; O Starodub; A D Petrescu; H Huang; A L McIntosh; G G Martin; H Chao; A B Kier; F Schroeder
Journal:  Prog Lipid Res       Date:  2001-11       Impact factor: 16.195

5.  Deficiencies in sex-regulated expression and levels of two hepatic sterol carrier proteins in a murine model of Niemann-Pick type C disease.

Authors:  C F Roff; A Pastuszyn; J F Strauss; J T Billheimer; M T Vanier; R O Brady; T J Scallen; P G Pentchev
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

6.  A potential role for sterol carrier protein-2 in cholesterol transfer to mitochondria.

Authors:  A M Gallegos; J K Schoer; O Starodub; A B Kier; J T Billheimer; F Schroeder
Journal:  Chem Phys Lipids       Date:  2000-03       Impact factor: 3.329

7.  Disruption of the sterol carrier protein 2 gene in mice impairs biliary lipid and hepatic cholesterol metabolism.

Authors:  M Fuchs; A Hafer; C Münch; F Kannenberg; S Teichmann; J Scheibner; E F Stange; U Seedorf
Journal:  J Biol Chem       Date:  2001-10-22       Impact factor: 5.157

8.  Relative contributions of L-FABP, SCP-2/SCP-x, or both to hepatic biliary phenotype of female mice.

Authors:  Gregory G Martin; Danilo Landrock; Kerstin K Landrock; Philip N Howles; Barbara P Atshaves; Ann B Kier; Friedhelm Schroeder
Journal:  Arch Biochem Biophys       Date:  2015-11-02       Impact factor: 4.013

Review 9.  Sterol carrier protein-2: new roles in regulating lipid rafts and signaling.

Authors:  Friedhelm Schroeder; Barbara P Atshaves; Avery L McIntosh; Adalberto M Gallegos; Stephen M Storey; Rebecca D Parr; John R Jefferson; Judith M Ball; Ann B Kier
Journal:  Biochim Biophys Acta       Date:  2007-04-12

10.  The immunohistochemical localization of the non-specific lipid transfer protein (sterol carrier protein-2) in rat small intestine enterocytes.

Authors:  F S Wouters; M Markman; P de Graaf; H Hauser; H F Tabak; K W Wirtz; A F Moorman
Journal:  Biochim Biophys Acta       Date:  1995-11-16
View more
  2 in total

1.  Sex-specific hepatic lipid and bile acid metabolism alterations in Fancd2-deficient mice following dietary challenge.

Authors:  Elizabeth S Moore; Erin K Daugherity; David I Karambizi; Bethany P Cummings; Erica Behling-Kelly; Deanna M W Schaefer; Teresa L Southard; Joseph W McFadden; Robert S Weiss
Journal:  J Biol Chem       Date:  2019-08-21       Impact factor: 5.157

2.  Identification of Key Pathways and Genes in Obesity Using Bioinformatics Analysis and Molecular Docking Studies.

Authors:  Harish Joshi; Basavaraj Vastrad; Nidhi Joshi; Chanabasayya Vastrad; Anandkumar Tengli; Iranna Kotturshetti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-24       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.